ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free MDG1 Stock Alerts €1.50 -0.09 (-5.64%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range€1.45▼€1.6250-Day Range€1.45▼€2.3652-Week Range€1.35▼€2.90Volume44,837 shsAverage Volume306,207 shsMarket Capitalization$36.96 millionP/E RatioN/ADividend Yield1.31%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Medigene alerts: Email Address Ad WealthPressMassive breakthrough for options traders.A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. Click here to see this stunning development for yourself. About Medigene Stock (ETR:MDG1)Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.Read More MDG1 Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDG1 Stock News HeadlinesApril 26, 2024 | finance.yahoo.comMedigene AG reports Financial Results and Business Update for Q1 2024April 25, 2024 | finance.yahoo.comMedigene presents streamlined 6-day, high stemness TCR-T therapy production processApril 28, 2024 | WealthPress (Ad)Massive breakthrough for options traders.A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. April 22, 2024 | finanznachrichten.dePTA-Adhoc: Medigene AG: Medigene AG führt Bezugsrechtskapitalerhöhung mit Backstop-Vereinbarung durchApril 17, 2024 | finance.yahoo.comMedigene to Present at Upcoming Scientific ConferencesApril 8, 2024 | finance.yahoo.comMedigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024April 4, 2024 | finanznachrichten.deMedigene: 2024 steht im Zeichen von MDG1015, BioNTech und der FinanzierungApril 4, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG sichert sich europäisches Patent für ihre iM-TCR-TechnologieApril 28, 2024 | WealthPress (Ad)Massive breakthrough for options traders.A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. April 4, 2024 | finance.yahoo.comMedigene AG Secures European Patent for its iM-TCR TechnologyMarch 28, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG gibt Finanzergebnisse für das Geschäftsjahr 2023 und Unternehmens-Update bekanntMarch 28, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG gibt -2-March 26, 2024 | finance.yahoo.comWe Think Medigene (ETR:MDG1) Needs To Drive Business Growth CarefullyMarch 19, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG nimmt an der H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference teilMarch 18, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 am 28. März 2024March 18, 2024 | finance.yahoo.comMedigene AG to report full year 2023 financial results on March 28, 2024March 6, 2024 | finance.yahoo.comMedigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual MeetingMarch 4, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene erweitert Patentportfolio in Japan um iM-TCR-Technologie zur Kontrolle der TCR-T-Sicherheit und -WirksamkeitFebruary 29, 2024 | finanznachrichten.deMedigene AG: Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T TherapiesFebruary 29, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene zeigt auf dem CAR-TCR Summit Europe innovative Ansätze zur Entwicklung differenzierter TCR-T-TherapienFebruary 29, 2024 | markets.businessinsider.comMedigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T TherapiesFebruary 19, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene präsentiert auf folgenden KonferenzenFebruary 19, 2024 | finance.yahoo.comMedigene to Present at Upcoming ConferencesFebruary 12, 2024 | finanznachrichten.dePTA-News: Medigene AG: Medigene gibt Auswahl der Anwendungsgebiete für die klinische Entwicklung der TCR-T-Therapie bei soliden Tumoren bekanntFebruary 12, 2024 | finanznachrichten.deMedigene AG: Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsFebruary 12, 2024 | uk.finance.yahoo.comMedigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsFebruary 12, 2024 | finance.yahoo.comMedigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid TumorsSee More Headlines Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CUSIPN/A CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income$-16,180,000.00 Net Margins-268.10% Pretax MarginN/A Return on Equity-55.69% Return on Assets-24.21% Debt Debt-to-Equity Ratio14.00 Current Ratio2.53 Quick Ratio5.85 Sales & Book Value Annual Sales$6.03 million Price / Sales6.13 Cash Flow€1.10 per share Price / Cash Flow1.37 Book Value€0.86 per share Price / Book1.75Miscellaneous Outstanding Shares24,560,000Free FloatN/AMarket Cap$36.96 million OptionableNot Optionable Beta0.85 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Selwyn Ho MB BS (Age 53)MBBS, CEO & Member of Executive Management Board Comp: $384.47kDr. Dolores J. SchendelChief Scientific Officer, Member of Executive Management Board and Head of Research & DevelopmentDr. Ernst-Ludwig Winnacker (Age 83)Co-Founder & Chairman Scientific Advisory Board Comp: $20kDr. Birger KohlertChief Financial OfficerPamela KeckVice President of Investor Relations & Corporate CommunicationsDr. Kirsty Crame M.D.VP and Head of Clinical Research & DevelopmentMore ExecutivesKey CompetitorsGenfitEPA:GNFTBiotest AktiengesellschaftETR:BIOMorphoSysETR:MOREssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEView All Competitors MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed in 2024? Medigene's stock was trading at €1.53 at the beginning of 2024. Since then, MDG1 stock has decreased by 1.3% and is now trading at €1.51. View the best growth stocks for 2024 here. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Apellis Pharmaceuticals (APLS), Aquinox Pharmaceuticals (AQXP). This page (ETR:MDG1) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
